Can Statin Medication Lower The Risk Of Dementia? It May Be So In Those With AFIB
9 months, 2 weeks ago
5368
0
Posted on Jul 12, 2023, 3 p.m.
Article courtesy of Dr. Joel Kahn, MD, who is a Clinical Professor of Medicine at Wayne State University School of Medicine, one of the world's top cardiologists, a best-selling author, lecturer, and a leading expert in plant-based nutrition and holistic care.
Atrial fibrillation (AF) is a heart rhythm disorder that is linked to an increased risk of dementia, even in stroke-free patients. Many patients with atrial fibrillation take daily oral anticoagulant (OAC) medications like warfarin or direct-acting oral agents like Xarelto. Even with OAC medications, dementia is a risk.
The impact of statin therapy on dementia risk is unclear in AF patients receiving OAC medications. A new study sought to investigate the impact of statin therapy on dementia risk in AF patients receiving OAC.
STUDY:
Using the Korean National Health Insurance Service database, 91, 018 non-valvular AF (NVAF) patients from January 2013 to December 2017 were included in the analysis.
Of the total, 17 700 patients (19.4%) were in the statin therapy group, and 73 318 patients (80.6%) were in the non-statin therapy group. The primary endpoint was the occurrence of dementia. The median duration of follow-up was 2.1 years.
Statin therapy was associated with a significantly lower dementia risk of about 23% compared with non-statin therapy patients (with a stroke risk score called CHA2DS2-VASc of ≥ 2).
The statin therapy group had a significantly lower dementia risk in a dose-dependent relationship compared with the non-statin therapy group.
CONCLUSIONS:
In NVAF patients who received OAC, statin therapy lowered the dementia risk compared with no statin therapy. Furthermore, statin therapy is associated with a dose-dependent reduction in dementia risk.
NVAF is a very common and potentially serious heart rhythm disorder that can increase the risk of both stroke and dementia. The use of statins is promising in this group, particularly if at increased stroke risk, even while on OAC medications.
About the author: At his core, Dr. Joel Kahn believes that plant-based nutrition is the most powerful source of preventative medicine on the planet. Having practiced traditional cardiology since 1983, it was only after his own commitment to a plant-based vegan diet that Dr. Kahn truly began to delve into the realm of non-traditional diagnostic tools, prevention tactics, and nutrition-based recovery protocols.
As with anything you read on the internet, this article should not be construed as medical advice; please talk to your doctor or primary care provider before changing your wellness routine. This article is not intended to provide a medical diagnosis, recommendation, treatment, or endorsement.
Opinion Disclaimer: The views and opinions expressed in this article are those of the author and do not necessarily reflect the official policy of WHN/A4M. Any content provided by guest authors is of their own opinion and is not intended to malign any religion, ethic group, club, organization, company, individual, or anyone or anything.
Content may be edited for style and length.
References/Sources/Materials provided by:
https://www.linkedin.com/in/joel-kahn-md-757a59225/
